Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christin Habigt

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal for Immunotherapy of Cancer|January 16, 2026
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumorsIgnacio Melero, Neeltje Steeghs, Ulrik Lassen, et al.
Frontiers in Oncology|March 28, 2025
Mapping MAGE-A4 expression in solid cancers for targeted therapiesChristin Habigt, Sylvie Rottey, Iben Spanggaard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2024
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell CarcinomaAaron R Hansen, Carlos A Gomez-Roca, Debbie G J Robbrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid TumorsIgnacio Melero, Josep Tabernero, Neeltje Steeghs, et al.
Cancer Research Communications|February 3, 2025
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic MelanomaEva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu, et al.
Ebiomedicine|October 12, 2024
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinomaLoic Verlingue, Antoine Italiano, Hans Prenen, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal for Immunotherapy of Cancer|January 16, 2026
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumorsIgnacio Melero, Neeltje Steeghs, Ulrik Lassen, et al.
Frontiers in Oncology|March 28, 2025
Mapping MAGE-A4 expression in solid cancers for targeted therapiesChristin Habigt, Sylvie Rottey, Iben Spanggaard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2024
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell CarcinomaAaron R Hansen, Carlos A Gomez-Roca, Debbie G J Robbrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid TumorsIgnacio Melero, Josep Tabernero, Neeltje Steeghs, et al.
Cancer Research Communications|February 3, 2025
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic MelanomaEva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu, et al.
Ebiomedicine|October 12, 2024
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinomaLoic Verlingue, Antoine Italiano, Hans Prenen, et al.
Pageof 1